Bridgebio Oncology Shares Drop 6.7% Amid Market Concerns, Seek Rebound After Clinical Milestones
Bridgebio Oncology Therapeut shares fall 6.7% as investors await new clinical data and partnership prospects, amid a broader biotech market dip.
- BRIDGEBIO ONCOLOGY THERAPEUT
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read